|
| |
Thrombotargets Corporation and Instituto Biomar to collaborate on
identification and optimization of new drug candidates
Thrombotargets Corp and Instituto Biomar today announced the signature of a
drug discovery collaboration agreement.
North Carolina, April 16th, 2007. Under the terms of this agreement, Instituto
Biomar will provide Thrombotargets Corp with its libraries of purified natural
products and extracts collection for its High Throughput Screening of Pathway
Activity (HTS-PA) in Thrombotargets’ technology . Thrombotargets will seek to
identify and optimize drug candidates for multiple targets that will be jointly
developed by both companies.
Thrombotargets ( www.thrombotargets.com
) is an innovative drug discovery and development group of biotech companies
developing new medicines based on advances in recombinant DNA and small molecule
drug technologies. Thrombotargets' programs leverage the company's haemostasis
expertise and are focused on inherited and acquired Hemorrhagic and Thrombotic
disorders.
Instituto Biomar (
www.institutobiomar.com ) has developed a research program with the
objective of exploiting the seas biodiversity, taking advantage of its expertise
in Marine Microbiology and Natural Product Chemistry, and its latest additions,
the Bioassay and Development Departments.
ABOUT THROMBOTARGETS
Thrombotargets group is comprised by three companies; Thrombotargets
Corporation (Durham, NC, USA.) is responsible for Drug Development and Business
Managment; Thrombotargets Europe (Barcelona, Spain) for Target Identification,
Lead Validation, Lead Optimization and High Througput Screening Development, and
Biotech Libraries (Girona, Spain) for engineered targeted libraries and HTS
Thrombotargets has developed and adapted to High Throughput Screening, a new
family of biological assays, for Hemostasia -to quantify simultaneously clot
formation and clot lysis-, for Atherosclerosis –to quantify low-density
lipoprotein modification- or for Oxidation -to quantify total antioxidant
capacity-. With these HTS platforms Thrombotargets group is creating a novel and
promising pipeline. At present, two of Thrombotargets most innovative drug
candidates (TT-103MH, a novel antibleeding recombinant protein granted by the US
FDA with an Orphan Drug Designation, and TT-105, a novel anticoagulant acting
through a new target) are undergoing Preclinical trials; TT-103MH will begin
Phase I clinical trials at the end of the year.
Contact:
Luis Caveda Ph.D.
Thrombotargets Corp.
COO
luiscaveda@thrombotargets.com
ABOUT INSTITUTO BIOMAR
Instituto Biomar was founded in January 1996, and its headquarters are located
in Onzonilla (León), 300 km. northwest of Madrid.
Instituto Biomar has developed an outstanding collection of fermentation
extracts from marine microorganisms, as well as a collection of compounds
produced by these microorganisms. Through very diverse collaborations the
company has identified in this collection compounds active in areas such as
cancer, neurodegenerative diseases, cosmetic and agricultural applications. In
the last two years Instituto Biomar has started work in the development of its
own portfolio of drug candidates, and is currently in the process of preclinical
evaluation of candidates for the Oncology program. The high chemical diversity
present in the collection, and the expertise in isolating active compounds from
the extracts are the tools for generating a solid pipeline in the different
areas of interest for the company.
Instituto Biomar has ongoing collaborations with outstanding private and public
research organizations worldwide for the discovery and development of novel
therapeutic agents.
Contact:
Antonio Fernández Ph D
Instituto Biomar
CEO
afernandez@institutobiomar.com
| |
|
